Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A fascinating new paper based on data from the Prostate Cancer DataBase Sweden provides important insight into the consequences of delayed diagnosis and potential under-treatment of men who are diagnosed with locally advanced prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: delayed, Diagnosis, locally advanced, mortality, prostate cancer-specific | 14 Comments »
A recent review article concludes with the statement, “5α-reductase inhibition does seem to have beneficial effects on prostate cancer incidence, and the role of [5α-reductase inhibitors (5-ARIs)] in combination with other agents should be further evaluated for the treatment of [castration-resistant prostate cancer (CRPC)].”
Filed under: Drugs in development, Management, Treatment | Tagged: 5-ARI, 5α-reductase, abiraterone, inhibitor | 5 Comments »
Perhaps to be more strictly accurate we should rephrase that heading as, “A diet high in whole-grain products did not appear to reduce the risk for prostate cancer among a large cohort of Danish men aged between 50 and 64 years.”
Filed under: Diagnosis, Prevention | Tagged: Danish, diet, risk, whole grain | 3 Comments »
The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) score was initially introduced in 2005 and validated in 2006 as a pre-treatment tool that could be used to assess risk for prostate cancer recurrence after first-line treatment.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CAPRA, CAPRA-S, prognosis, recurrence, risk, surgery | 5 Comments »
A research team at New York University School of Medicine has reported data suggesting that a single ultrasensitive PSA test result may be able to project risk for delayed biochemical recurrence (BCR) of prostate cancer at 3 years after a radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochgemical recurrence, prognosis, PSA, Treatment, ultrasensitive | 3 Comments »
Many prostate cancer patients and advocates will want to read yesterday’s article by New York Times correspondent Andrew Pollack entitled, “New drugs fight prostate cancer, but at high cost.” The article offers a commentary on recent advances in the treatment of advanced prostate cancer — and the economic consequences.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: advanced, cost, drugs | Comments Off
A team of researchers at Duke University have shown that most men with castration-resistant prostate cancer (mCRPC) express multiple epithelial proteins in their circulating T cells (CTCs).
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: circulating T-cells, CTC | Leave a Comment »
Prostate cancer patients in general, but most especially men receiving androgen deprivation therapy (ADT), experience symptoms and side effects of treatment that make it difficult to maintain their independence and quality of life. A recent review states that exercise may offset many of the side effects of ADT as well as those of the cancer [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: exercise, outcome, quality of life, side effects, Treatment | 2 Comments »
It has been known for years that marital status impacts the likelihood of stage at diagnosis and survival in a number of different types of cancer (prostate cancer included). However, a new study has now confirmed this in a large, US, population-based analysis of prostate cancer patients.
Filed under: Diagnosis, Management, Risk | Tagged: marital status, mortality, stage | Leave a Comment »
On December 5 to 7 this year, the National Institutes of Health (NIH) is to hold an NIH State-of-the-Science Conference on the role of active surveillance and watchful waiting in the management of men with supposedly localized prostate cancer. It is free and open to the public or it can be monitored by web cast.
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, watchful waiting | Leave a Comment »
A web site called GreatNonProfits is running a health competition through the end of June. We would like your help to use this competition to promote awareness of the services of Prostate Cancer International — particularly The “New” Prostate Cancer InfoLink and and the associated social network. So
Filed under: Uncategorized | Leave a Comment »
Any readers of this web site who have been using Google Health as a technology to store personal health data should click on this link.
Filed under: Uncategorized | Tagged: Google Health | Leave a Comment »
An article in Progrès en urologie states that the prostate cancer-specific mortality rate in France has been dropping by 2.5 percent per year.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: France, mortality, prostate cancer-specific | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site